Celldex Therapeutics (CLDX) Long-Term Investments (2016)

Celldex Therapeutics (CLDX) recorded quarterly Long-Term Investments of $1.8 million in Q4 2016.

Celldex Therapeutics (CLDX) Long-Term Investments (2016) Analysis & Trends

Celldex Therapeutics' Long-Term Investments history runs 1 years deep, the most recent figure standing at $1.8 million for Q4 2016.

In Q4 2016, Long-Term Investments changed N/A year-over-year to $1.8 million; the TTM figure through Dec 2016 stood at $1.8 million (changed N/A YoY), while the FY2016 annual figure was $1.8 million, changed N/A from the prior year.
Long-Term Investments was $1.8 million for Q4 2016 at Celldex Therapeutics.
In the past five years, Long-Term Investments ranged from a high of $1.8 million in Q4 2016 to a low of $1.8 million in Q4 2016.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	5.17 Mn
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	5.75 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Celldex Therapeutics	2.16 Bn	2.16 Bn	-1.44 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2016	1.80 Mn